Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Facilitated α-synuclein oligomer sharing among glial cells by a centrally acting connexin inhibitor attenuates a rapidly progressive multiple system atrophy-cerebellar type model by reducing the neuronal α-synuclein burden.

Acta neuropathologica communications·2025

Same author

The Impact of Intradialytic Exercise on Activities of Daily Living and Physical Function in Hospitalized Hemodialysis Patients: A Study of Efficacy and Safety.

JMA journal·2025

Same author

Effectiveness of rehabilitation in hospitalized hemodialysis patients as compared with rehabilitation in hospitalized patients not on hemodialysis: a retrospective cohort study.

Journal of nephrology·2025

Same author

Interleukin-19 Abrogates Experimental Autoimmune Encephalomyelitis by Attenuating Antigen-Presenting Cell Activation.

Frontiers in immunology·2021

Same author

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

Scientific reports·2021

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

[Therapeutic strategy against multiple sclerosis].

Akio Suzumura¹

¹Department of Neuroimmunology, RIEM, Nagoya University.

Rinsho Shinkeigaku = Clinical Neurology

|February 10, 2009

Summary

New strategies for multiple sclerosis (MS) involve boosting regulatory T cells (Treg) by inhibiting midkine and preventing axonal damage by targeting glutamate production. These approaches show promise in treating MS.

Area of Science:

Neuroimmunology
Autoimmune Diseases
Neuroprotection

Background:

The exact causes of multiple sclerosis (MS) are unknown, and current treatments do not offer a cure.
MS involves autoimmune processes attacking the central nervous system and axonal degeneration from early stages.
Regulatory T cells (Treg) are crucial for immune system self-tolerance and preventing autoimmune responses.

Purpose of the Study:

To explore novel therapeutic strategies for multiple sclerosis (MS).
To investigate methods for suppressing autoimmune processes and preventing axonal degeneration in MS.
To identify potential drug targets for MS treatment.

Main Methods:

Investigating the role of midkine in suppressing regulatory T cell (Treg) development.

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 25, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Utilizing RNA aptamers to inhibit midkine and assess effects on experimental autoimmune encephalomyelitis (EAE), an MS model.

Examining the role of glutamate, produced by glutaminase and released via gap-junctions, in axonal degeneration.

Evaluating the efficacy of glutaminase and gap-junction inhibitors as potential MS treatments.

Assessing the impact of Interferon-beta on glutamate production and axonal degeneration.

Main Results:

Midkine was found to suppress Treg development.
Suppression of midkine using RNA aptamers expanded Treg and alleviated EAE symptoms.
Glutamate, released by activated macrophages and microglia, is a key factor in axonal degeneration.
Inhibitors of glutaminase and gap-junctions show potential for MS treatment.
Interferon-beta reduces glutamate production, thereby mitigating axonal degeneration.

Conclusions:

Modulating midkine activity to expand Tregs offers a promising strategy for MS treatment.
Targeting glutamate production pathways presents a novel therapeutic avenue for preventing axonal damage in MS.
Interferon-beta demonstrates neuroprotective effects by inhibiting glutamate-mediated axonal degeneration.